Halozyme
Chemicals & Related Products · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
12390 El Camino Real, San Diego, Califor...Phone Number
(858) 794-8889Website
www.halozyme.comRevenue
$1.7 BillionStock Symbol
HALOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Halozyme
Halozyme Inc. is an American biotechnology and biopharmaceutical company specializing in the development and commercialization of advanced drug delivery technologies and enzyme-based therapeutic solutions. The organization focuses primarily on improving the administration of biologic medicines through proprietary technologies that enable subcutaneous drug delivery for therapies that traditionally require intravenous infusion. Through scientific innovation, strategic pharmaceutical partnerships, and proprietary platform technologies, the company has established a significant position within the global biotechnology and pharmaceutical ecosystem. The company was founded in San Diego, California and has evolved into a globally recognized biotechnology enterprise with extensive collaborations across the pharmaceutical industry. Halozymes business model combines internal therapeutic development with technology licensing arrangements that allow pharmaceutical partners to integrate Halozymes pRead more
Halozyme Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Halozyme your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Halozyme had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Halozyme is spiking on competitors!
Earning: See what the market has to say on Halozyme recently announced quarterly report
Check if Halozyme has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Halozyme has new funding data
Halozyme, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Halozyme launches new products
Congratulate Masked Content for being promoted to Masked Content at Halozyme
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Halozyme
Compare insights from companies similar to Halozyme, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Halozyme
$1.7B
201-500
Public
$1.1B
1998
JB
Joanne BeckChief Operating Officer, Hypercon (Previously Elektrofi)
$19.9M
51-200
Private
$300M
2016
RC
Ryan CarteExecutive Vice President & General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
Halozyme is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Halozyme is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Halozyme.
Halozyme financials insights
Gather financial insights about Halozyme, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Corporate Investment
$5.5M
Stock Offering
$38.2M
2010
Stock Offering
$60M
2012
Stock Offering
$81.8M
2014
Debt
$50M
Stock Offering
$107.8M
2016
Debt
$150M
2017
Stock Offering
$135M
2019
Debt
$400M
Halozyme Tech Stack
A closer look at the technologies used by Halozyme
See more technologies
Most Recent Scoops
Project
Halozyme announced that PHESGO delivered 18% growth in H1 2026, with global conversion reaching 54% across 85 launch countries, as Roche reiterated its expectation for at least 60% conversion at peak and highlighted PHESGO as a key component of the franchise's long-term durability.
Pharmaceuticals
Partnership
Halozyme has signed five new collaboration and licensing agreements in Q2 2026 and July 2026, representing the fastest pace of new collaboration agreements in the company's history, with three of the five agreements being for its ENHANZE platform, including new deals with GSK, Incyte, and a third confidential partner.
Partnership, Contracts
Project
Halozyme announced that VYVGART is now the first and only therapy approved across all generalized myasthenia gravis serotypes, including seronegative patients following US approval in May 2026, expanding the addressable patient opportunity by approximately 11,000 patients, with positive Phase III data in ocular myasthenia gravis further highlighting future growth potential.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Halozyme announced that Johnson & Johnson highlighted rapid uptake of RYBREVANT FASPRO in Q2 2026, contributing to 62% year-over-year growth, with a permanent J-code awarded on July 1, 2026, expected to support further growth acceleration in upcoming quarters.
Earnings, Pharmaceuticals, Finance
Project
Pharmaceuticals
Halozyme News & Media
Halozyme to Participate at Upcoming Investor Conferences
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Chief Financial Officer, are scheduled to participate and host investor meetings at the...Halozyme Appoints Dannielle Appelhans to its Board of Directors
SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings more than 20 years of executive leadership across the biotechnology and pharmaceutical...Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know
Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 18.1% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year financial guidance.Halozyme to Report Second Quarter 2026 Financial and Operating Results
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, following the close of trading. Halozyme will host a conference call on...
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Halozyme
Sign Up For FreeTo access detailed company insights
Halozyme Inc. is an American biotechnology and biopharmaceutical company specializing in the development and commercialization of advanced drug delivery technologies and enzyme-based therapeutic solutions. The organization focuses primarily on improving the administration of biologic medicines through proprietary technologies that enable subcutaneo... Read More
